Patent US2020117A successfully refreshed from Google Patents.
US5130141A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions for and methods of treating muscle degeneration and weakness
Assignee: Individual
•
Filing: 1991-05-30
•
Granted: 1992-07-14
•
Expires: 2011-05-30
Abstract
Abstract Compositions for and methods of treating muscle weakness and degeneration are described. Such compositions include myogenic cells which are administered by the described methods to one or more affected muscles.
Inventors
- 👤 Peter K. Law
- 👤 Tena G. Goodwin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:37
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/34
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
84 words
A method of treating muscle degeneration and weakness in a host, comprising the steps of: culturing genetically normal myogenic cells from donors to produce a supply of the myogenic cells comprising myoblasts, myotubes, and young muscle fiber cells; administering a therapeutically effective dosage of an immunosuppressant to the host; and thereafter selecting and administering from the said supply a therapeutically effective dosage of myogenic cells to at least one myopathic muscle of the host, whereby muscle functions, locomotive patterns, and respiratory functions are improved.
Claim 2
Independent Claim
84 words
A method of treating muscle degeneration and weakness in a host, comprising the steps of: culturing genetically normal myogenic cells from donors to produce a supply of the myogenic cells comprising myoblasts, myotubes, and young muscle fiber cells; administering a therapeutically effective dosage of an immunosuppressant to the host; and thereafter selecting and administering from the said supply a therapeutically effective dosage of myogenic cells to at least one myopathic muscle of the host, whereby muscle functions, locomotive patterns, and respiratory functions are improved.
Claim 3
Dependent Claim
22 words
The method of claim 1, wherein said selected, therapeutically effective dosage of the cultured myogenic cells is approximately 10 6 per ml.
Claim 4
Dependent Claim
43 words
The method of claim 1, wherein said cultured myogenic cells are obtained from donors selected from a genetically normal group, comprising the parents of the host, siblings of the host, and the host prior to the onset of the muscle degeneration and weakness.
Claim 5
Dependent Claim
10 words
The method of claim 1, wherein said immunosuppressant comprises cyclosporin-A.
Claim 6
Dependent Claim
15 words
The method of claim 1, wherein said cultured myogenic cells are histocompatible with the host.
Claim 7
Dependent Claim
15 words
The method of claim 1, wherein said cultured myogenic cells are histoincompatible with the host.
Claim 8
Independent Claim
91 words
A method of treating muscle degeneration and weakness in a host, comprising the steps of: cloning genetically normal myogenic cells from donors, maintaining the cloned myogenic cells in a culture medium to produce a supply of the cloned myogenic cells comprising myoblasts, myotubes, and young muscle fiber cells; administering a therapeutically effective dosage of an immunosuppressant; and thereafter selecting and administering from the said supply a therapeutically effective dosage of myogenic cells to at least one myopathic muscle of a host, whereby muscle functions, locomotive patterns, and respiratory functions are improved.
Claim 9
Independent Claim
91 words
A method of treating muscle degeneration and weakness in a host, comprising the steps of: cloning genetically normal myogenic cells from donors, maintaining the cloned myogenic cells in a culture medium to produce a supply of the cloned myogenic cells comprising myoblasts, myotubes, and young muscle fiber cells; administering a therapeutically effective dosage of an immunosuppressant; and thereafter selecting and administering from the said supply a therapeutically effective dosage of myogenic cells to at least one myopathic muscle of a host, whereby muscle functions, locomotive patterns, and respiratory functions are improved.
Claim 10
Dependent Claim
42 words
The method of claim 7, wherein said myogenic cells are cloned from muscle belonging to donors selected from a genetically normal group, comprising parents and siblings of the host and the host prior to the onset of the muscle degeneration and weakness.
Claim 11
Dependent Claim
22 words
The method of claim 7, wherein said selected, therapeutically effective dosage of the cloned myogenic cells is approximately 10 6 per ml.
Claim 12
Dependent Claim
10 words
The method of claim 7, wherein said immunosuppressant comprises cyclosporin-A.
Claim 13
Dependent Claim
15 words
The method of claim 7, wherein said cloned myogenic cells are histocompatible with the host.
Claim 14
Dependent Claim
15 words
The method of claim 7, wherein said cloned myogenic cells are histoincompatible with the host.
Claim 15
Dependent Claim
56 words
A composition for the treatment of muscle degeneration and weakness of a host, comprising: a supply quantum of cultured genetically normal myogenic cells from donors comprising myoblasts, myotubes, and young muscle fiber cells; and a therapeutically effective dosage of the myogenic cells from said supply for administration to at least one myopathic muscle of a host.
Claim 16
Dependent Claim
56 words
A composition for the treatment of muscle degeneration and weakness of a host, comprising: a supply quantum of cultured genetically normal myogenic cells from donors comprising myoblasts, myotubes, and young muscle fiber cells; and a therapeutically effective dosage of the myogenic cells from said supply for administration to at least one myopathic muscle of a host.
Claim 17
Dependent Claim
23 words
The composition defined in claim 13, wherein said selected therapeutically effective dosage of the cultured myogenic cells is approximately 10 6 per ml.
Claim 18
Dependent Claim
44 words
The composition defined in claim 13, wherein said cultured myogenic cells are obtained from donors selected from a genetically normal group, comprising the parents of the host, siblings of the host, and the host prior to the onset of the muscle degeneration and weakness.
Claim 19
Dependent Claim
16 words
The composition defined in claim 13, wherein said cultured myogenic cells are histocompatible with the host.
Claim 20
Dependent Claim
16 words
The composition defined in claim 13, wherein said cultured myogenic cells are histoincompatible with the host.
Claim 21
Dependent Claim
57 words
A composition for the treatment of muscle degeneration and weakness of a host, comprising: a supply quantum of cloned genetically normal myogenic cells from donors comprising myoblasts, myotubes, and young muscle fiber cells; and a therapeutically effective dosage of the myogenic cells selected from said supply for administration to at least one myopathic muscle of a host.
Claim 22
Dependent Claim
57 words
A composition for the treatment of muscle degeneration and weakness of a host, comprising: a supply quantum of cloned genetically normal myogenic cells from donors comprising myoblasts, myotubes, and young muscle fiber cells; and a therapeutically effective dosage of the myogenic cells selected from said supply for administration to at least one myopathic muscle of a host.
Claim 23
Dependent Claim
23 words
The composition defined in claim 18, wherein said selected therapeutically effective dosage of the cloned myogenic cells is approximately 10 6 per ml.
Claim 24
Dependent Claim
44 words
The composition defined in claim 18, wherein said cloned myogenic cells are obtained from donors selected from a genetically normal group, comprising the parents of the host, siblings of the host, and the host prior to the onset of the muscle degeneration and weakness.
Claim 25
Dependent Claim
16 words
The composition defined in claim 18, wherein said cloned myogenic cells are histocompatible with the host.
Claim 26
Dependent Claim
16 words
The composition defined in claim 18, wherein said cloned myogenic cells are histoincompatible with the host.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-07-14 | 1996-01-13 | 1996-07-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-07-14 | 2000-01-13 | 2000-07-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-07-14 | 2004-01-13 | 2004-07-14 | $7700.00 | Window Closed / Lapsed |